Literature DB >> 2079855

Analysis of immune response to red blood cell antigens in multitransfused patients with different diseases.

H Seyfried1, I Walewska.   

Abstract

The rate of alloimmunization to red blood cell antigens in 1502 multitransfused patients, mainly with blood disorders, was analyzed in a retrospective study. The overall incidence of alloantibodies was 5.7%. Three groups of patients were identified with different potential for antibody production. The lowest probability (1.8%) of alloimmunization was found in the group of patients with lymphoproliferative syndromes, acute myeloid leukaemia and burn disease. The highest probability (33.4%) of immune response to red blood cell antigens was found in patients with AIHA, liver cirrhosis and myelodysplastic syndrome. In the group of patients with chronic myeloid leukaemia, pancytopenias, anaemias of various origin and aplastic anaemia the probability of alloimmunization ranged from 5.7% to 13.6%. A possible role of genetic-factors and immune competence status in post-transfusion alloimmunization is briefly discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2079855

Source DB:  PubMed          Journal:  Mater Med Pol        ISSN: 0025-5246


  14 in total

1.  Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs.

Authors:  Nicole H Smith; Eldad A Hod; Steven L Spitalnik; James C Zimring; Jeanne E Hendrickson
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

2.  Murine Red Blood Cells Lack Ligands for B Cell Siglecs, Allowing Strong Activation by Erythrocyte Surface Antigens.

Authors:  Fernando Spiller; Corwin M Nycholat; Chika Kikuchi; James C Paulson; Matthew S Macauley
Journal:  J Immunol       Date:  2017-12-29       Impact factor: 5.422

Review 3.  Red blood cell transfusion risks in patients with end-stage renal disease.

Authors:  Yvette C Tanhehco; Jeffrey S Berns
Journal:  Semin Dial       Date:  2012-06-11       Impact factor: 3.455

4.  Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database.

Authors:  Matthew S Karafin; Matt Westlake; Ronald G Hauser; Christopher A Tormey; Philip J Norris; Nareg H Roubinian; Yanyun Wu; Darrell J Triulzi; Steve Kleinman; Jeanne E Hendrickson
Journal:  Br J Haematol       Date:  2018-04-19       Impact factor: 6.998

5.  Transfusion of RhD-incompatible blood components in RhD-negative blood marrow transplant recipients.

Authors:  M Asfour; Aida Narvios; Benjamin Lichtiger
Journal:  MedGenMed       Date:  2004-07-13

6.  Erythrocyte Alloimmunization and Autoimmunization among Blood Donors and Recipients visiting a Tertiary Care Hospital.

Authors:  Daljit Kaur; Lovenish Bains; Manoj Kandwal; Indu Parmar
Journal:  J Clin Diagn Res       Date:  2017-03-01

7.  Storage of murine red blood cells enhances alloantibody responses to an erythroid-specific model antigen.

Authors:  Jeanne E Hendrickson; Eldad A Hod; Steven L Spitalnik; Christopher D Hillyer; James C Zimring
Journal:  Transfusion       Date:  2009-11-09       Impact factor: 3.157

8.  Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice.

Authors:  Weili Bao; Jin Yu; Susanne Heck; Karina Yazdanbakhsh
Journal:  Blood       Date:  2009-03-31       Impact factor: 22.113

9.  The spleen plays a central role in primary humoral alloimmunization to transfused mHEL red blood cells.

Authors:  Jeanne E Hendrickson; Natia Saakadze; Chantel M Cadwell; Jason W Upton; Edward S Mocarski; Christopher D Hillyer; James C Zimring
Journal:  Transfusion       Date:  2009-08       Impact factor: 3.157

10.  Antigen Density Dictates Immune Responsiveness following Red Blood Cell Transfusion.

Authors:  Connie M Arthur; Seema R Patel; Nicole H Smith; Ashley Bennett; Nourine A Kamili; Amanda Mener; Christian Gerner-Smidt; Harold C Sullivan; J Scott Hale; Andreas Wieland; Benjamin Youngblood; James C Zimring; Jeanne E Hendrickson; Sean R Stowell
Journal:  J Immunol       Date:  2017-03-01       Impact factor: 5.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.